Table 5.
Hemostatic treatments (patient level)
| Treatment | Patients, N (%) | Treatment days, median (IQR) | Cumulative dose per patient, median (IQR) |
|---|---|---|---|
| None | 21 (21) | — | — |
| No bypassing agents | 34 (33) | — | — |
| rFVIIa concentrate (mg) | 63 (62) | 13 (4-27) | 210 (56-491) |
| APCC (U) | 22 (22) | 9 (4-20) | 62 500 (22 750-111 000) |
| hFVIII (IU) | 15 (15) | 7 (3-19) | 36 000 (10 000-133 000) |
| Desmopressin (mg) | 2 (2) | 2 | 15, 29 |
| Tranexamic acid (g) | 31 (30) | 15 (8-34) | 28 (18-60) |
| PRBC (no.) | 47 (46) | 3 (1-6) | 6 (2-12) |
| PC (no.) | 6 (6) | 2 (1-3) | 4 (2-7) |
| FFP (no.) | 4 (4) | 2 (1-2) | 5 (3-9) |
| Fibrinogen concentrate (g) | 1 (1) | 7 | 28 |
Some patients received combinations of treatments.
FFP, fresh frozen plasma; IQR, interquartile range; PC, platelet concentrate; PRBC, packed red blood cells.